Evidence map›Paper›PMID 35492248›Full record

ArticleCell reports. Medicine2022

Efficacy of glucagon-like peptide-1 and estrogen dual agonist in pancreatic islets protection and pre-clinical models of insulin-deficient diabetes.

Taylor Fuselier, Paula Mota de Sa, M M Fahd Qadir, Beibei Xu, Camille Allard, Mathew M Meyers, Joseph P Tiano, Bin S Yang, Vasily Gelfanov, Sarah H Lindsey and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Taylor FuselierDeming Department of Medicine, Section of Endocrinology and Metabolism, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA.
Paula Mota de SaDeming Department of Medicine, Section of Endocrinology and Metabolism, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA; Tulane Center of Excellence in Sex-Based Biology & Medicine, New Orleans, LA 70112, USA; Southeast Louisiana Veterans Healthcare System Medical Center, New Orleans, LA 70119, USA.
M M Fahd QadirDeming Department of Medicine, Section of Endocrinology and Metabolism, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA; Tulane Center of Excellence in Sex-Based Biology & Medicine, New Orleans, LA 70112, USA; Southeast Louisiana Veterans Healthcare System Medical Center, New Orleans, LA 70119, USA.
Beibei XuDeming Department of Medicine, Section of Endocrinology and Metabolism, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA.
Camille AllardDeming Department of Medicine, Section of Endocrinology and Metabolism, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA.
Mathew M MeyersDepartment of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Joseph P TianoDepartment of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Bin S YangNovo Nordisk Research Center Indianapolis, Indianapolis, IN 46241, USA.
Vasily GelfanovNovo Nordisk Research Center Indianapolis, Indianapolis, IN 46241, USA.
Sarah H LindseyTulane Center of Excellence in Sex-Based Biology & Medicine, New Orleans, LA 70112, USA; Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Richard D DimarchiDepartment of Chemistry, Indiana University, Bloomington, IN 47405, USA.
Franck Mauvais-JarvisDeming Department of Medicine, Section of Endocrinology and Metabolism, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA; Tulane Center of Excellence in Sex-Based Biology & Medicine, New Orleans, LA 70112, USA; Southeast Louisiana Veterans Healthcare System Medical Center, New Orleans, LA 70119, USA. Electronic address: fmauvais@tulane.edu.
Tulane University · USNorthwestern University · USNovo Nordisk (United States) · USIndiana University Bloomington · US

Funding

The Human Islet Distribution Coordinating Center (UC4)UC4DK098085 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI EVANS-MOLINA, CARMELLA, NILAND, JOYCE CAROL · 2012 to 2017
$25.6M
Targeting the estrogen receptor-α to protect functional β-cell mass in womenR01DK074970 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI Franck Mauvais-Jarvis · 2007 to 2026
$6.0M
Eliciting Estrogen's Protective Vascular EffectsR01HL133619 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI LINDSEY, SARAH H. · 2017 to 2021
$2.2M
Repurposing estrogens to improve pancreatic islet transplantationR01DK107444 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI MAUVAIS-JARVIS, FRANCK · 2016 to 2019
$1.5M
Functional Proteomics by Reverse Phase Protein Array in CancerR50CA221675 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LU, YILING · 2017 to 2021
$726k
The role of the androgen receptor in insulin secretionI01BX003725 · VA · SOUTHEAST LOUISIANA VETERANS HEALTH CARE · PI MAUVAIS-JARVIS, FRANCK · 2018 to 2022
–
BLRD VA I01 BX003725NCI NIH HHS R50 CA221675NHLBI NIH HHS R01 HL133619NIDDK NIH HHS R01 DK074970NIDDK NIH HHS R01 DK107444NIDDK NIH HHS UC4 DK098085
6 · The paper itself

Abstract

We study the efficacy of a glucagon-like peptide-1 (GLP-1) and estrogen dual agonist (GLP1-E2) in pancreatic islet protection. GLP1-E2 provides superior protection from insulin-deficient diabetes induced by multiple low-dose streptozotocin (MLD-STZ-diabetes) and by the Akita mutation in mice than a GLP-1 monoagonist. GLP1-E2 does not protect from MLD-STZ-diabetes in estrogen receptor-α (ERα)-deficient mice and fails to prevent diabetes in Akita mice following GLP-1 receptor (GLP-1R) antagonism, demonstrating the requirement of GLP-1R and ERα for GLP1-E2 antidiabetic actions. In the MIN6 β cell model, GLP1-E2 activates estrogen action following clathrin-dependent, GLP-1R-mediated internalization and lysosomal acidification. In cultured human islet, proteomic bioinformatic analysis reveals that GLP1-E2 amplifies the antiapoptotic pathways activated by monoagonists. However, in cultured mouse islets, GLP1-E2 provides antiapoptotic protection similar to monoagonists. Thus, GLP1-E2 promotes GLP-1 and E2 antiapoptotic signals in cultured islets, but

Indexed as

Diabetes MellitusIslets of LangerhansAnimalsEstrogen Receptor alphaEstrogensGlucagon-Like Peptide 1InsulinInsulin, Regular, HumanMiceProteomicsStreptozocinEstrogen Receptor alphaEstrogensGlucagon-Like Peptide 1InsulinInsulin, Regular, HumanStreptozocindiabetesdual agonistestrogenfusion peptidesGLP-1isletpeptidesproteomicsRPPAβ cell

Identifiers

PMID35492248
PMCPMC9043999
OpenAlexW4225321739

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.